ACROBiosystems
Generated by Meeveem AI
"Leading global provider of innovative biological reagents accelerating therapeutic drug development"
Newark, DE
•501 - 1000 Employees
•Contract Research
About ACROBiosystems
ACROBiosystems provides biological reagents and services to biopharmaceutical companies and research institutions globally. The company operates an integrated protein development platform combining AI-driven design, high-throughput screening, and quality control to accelerate targeted therapies, immunotherapeutic drugs, and cell and gene therapies from discovery to clinic. Founded in 2010 and publicly listed in 2021, ACROBiosystems maintains GMP facilities across 15 cities in the United States, Switzerland, United Kingdom, and Germany. Serving pharmaceutical enterprises including Pfizer, Novartis, and Johnson & Johnson, the company delivers recombinant proteins, antibodies, and analytical services under ISO certified standards.
869
Team Members
2010
Founded
Contract Research
Sector
Hybrid
Work Environment
Our Vision
A world where biopharmaceutical breakthroughs reach patients faster, enabled by universally accessible, highest quality biological tools that eliminate barriers in drug development and clinical translation.
Our Mission
ACROBiosystems accelerates therapeutic drug development by providing innovative biological reagents, GMP-grade materials, and analytical services that overcome challenges from discovery to the clinic.